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Abstract 
Leptin has been shown to upregulate the fat mass and obesity-associated protein (FTO) in the 
cardiomyocyte, an effect that has been linked to cardiomyocyte hypertrophy. In this current 
study, we sought to determine if other cardiomyocyte hypertrophic agonists could upregulate 
FTO. Angiotensin II displayed the ability to significantly upregulate mRNA expression and 
protein expression of FTO. Thus, in this study, we explored the cellular mechanisms behind 
angiotensin II-induced FTO upregulation. 
Angiotensin II-induced FTO upregulation was attenuated by 10 µM valsartan, an AT-1 
receptor antagonist, 5 µM EMD87580, a sodium-hydrogen exchanger isoform 1 (NHE-1) 
inhibitor, and 2 nM FK506, a calcineurin inhibitor. This data suggests that angiotensin II-
induced FTO upregulation is AT-1 receptor mediated and has a signal transduction pathway 
involving the NHE-1/calcineurin system. All the above agents also abolished angiotensin II-
induced hypertrophy. 
In addition, our studies show that a super-ovine leptin receptor antagonist (LRA; 100 nM) and 
JAK2 inhibitor, 50 µM AG490, also attenuate angiotensin II-induced FTO upregulation. These 
results implicate the leptin-JAK2-STAT3 signalling system in angiotensin II-induced FTO 
upregulation. The above agents also abolished angiotensin II-induced hypertrophy. 
The data suggests that NHE-1/calcineurin as well as leptin-mediated JAK2/STAT3 signalling 
play a critical role in angiotensin II-induced FTO upregulation. 
Keywords: Cardiac hypertrophy, heart failure, cardiomyocytes, angiotensin II, sodium-
hydrogen exchanger, calcineurin, leptin, JAK2, fat mass and obesity-associated protein 
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Chapter 1  
1  Introduction  
Cardiovascular disease is among the leading causes of death in Canada. Since the end of 
the late 1970s, hospital discharges for heart failure have been progressively increasing 
(Roger et al., 2011). This increase has been attributed to the development of new and 
effective therapeutic strategies for dealing with heart attacks. To clarify, more patients are 
surviving heart attacks and other acute ischemic diseases and as a result, these patients go 
on to develop heart failure due to the compromised myocardial function caused by the 
initial ischemic event (McMurray & Pfeffer, 2005). As well, heart failure is a disease that 
is most prevalent among the aged population. With the advancement of medicine, and 
beneficial lifestyle modifications, Canadians are living longer (McMurray & Pfeffer, 
2005). This increased life expectancy has also increased the incidence of heart failure. 
Given that we are in the midst of an aging baby boomer population—as more than 14.8% 
of Canada’s population is over the age of 65 (Statistics Canada, 2011)—heart failure is and 
will continue to be an inevitable burden on patients, their families and the health care 
system. Therefore, heart failure is a significant health concern to Canadians, and an urgent 
health issue that must be actively researched.  
 
1.1  Cardiac hypertrophy  
Cardiac hypertrophy is one of the few mechanisms employed by the heart when 
responding to a hemodynamic burden. Essentially the heart increases in mass through the 
growth of existing cells rather than division of these cells as would occur in hyperplasia. 
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This increase in mass serves to bear the extra load on the heart (Lorell & Carabello, 2000). 
Depending on the nature of the hemodynamic load, hypertrophy of the heart can manifest 
in two morphologically distinct ways; concentric hypertrophy and eccentric hypertrophy. 
Pressure overload constitutes one of the two major hemodynamic loads that can burden the 
heart. Pressure overload results in an increase in synthesis of sarcomeres—the smallest 
functional unit of the cardiomyocyte responsible for its contractile properties. These 
sarcomeres are arranged in a parallel orientation, resulting in an increase in width of the 
cardiomyocyte and an increase in the thickness of the myocardial wall. This is known as 
concentric hypertrophy. Volume overload, the other major hemodynamic load, also results 
in an increase in synthesis of sarcomeres though the arrangement of the sarcomeres differs 
in comparison to the arrangement in a pressure overload situation. During volume 
overload, the newly synthesized sarcomeres are organized in a series resulting in an 
increase in ventricular volume (Lorell & Carabello, 2000). Pathophysiological conditions 
in which pressure overload occurs are hypertension or aortic stenosis. These are conditions 
where the systolic stress otherwise known as afterload rises to supraphysiological levels. 
This pressure overload induces a thickening of the wall which, according to LaPlace’s Law, 
will normalize the systolic stress thus preserving the ejection fraction of the heart (Frey et 
al., 2004). Volume overload occurs in pathophysiological conditions such as mitral 
regurgitation and aortic regurgitation (Lorell & Carabello, 2000). In both of these 
pathological conditions, the valves responsible for facilitating the unidirectional flow of 
blood through the heart to the rest of the body are dysfunctional, thus allowing blood to 
flow back into the heart. The result is an accumulation of blood in the heart otherwise 
known as volume overload. The volume overload serves as a biomechanical signal, 
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resulting in the longitudinal growth of the cardiomyocytes (Frey et al., 2004). This results 
in the ventricular cavity increasing in volume in a process called ventricular dilation (Lorell 
& Carabello, 2000). This change in structure will allow the heart to restore stroke volume 
(Lorell & Carabello, 2000).  
 There is an abundance of intracellular signaling pathways that induce cardiac 
hypertrophy, perhaps suggesting the importance of the hypertrophic process. Some of the 
main pathways that have been studied extensively are the mitogen-activated protein kinase 
(MAPK) pathway, phosphatidylinositol 3 kinase-Akt pathway and calcineurin-nuclear 
factor of activated T cells (NFAT) pathway (Bernardo et al., 2010). The two mechanisms 
responsible for activating these intracellular pathways are; biomechanical/stretch-sensitive 
mechanisms and/or neurohumoral mechanisms (Heineke & Molkentin, 2006). Although 
not fully understood, biomechanical signals such as stretch can be sensed by membrane 
receptors that are intrinsically unique in structure such that they respond to the stretch 
signal by activating some of these intracellular signalling pathways. The neurohumoral 
mechanisms are associated with the release of chemokines, growth factors and hormones 
that are sensed by receptors on the cell membrane (Heineke & Molkentin, 2006). These 
receptors in turn, activate second messengers and effectors that will participate in an 
intracellular signaling cascade culminating in the hypertrophic response. The signaling 
pathways activated by both mechanisms activate the hypertrophic growth process by 
modulating the expression of specific genes in the nucleus and increasing protein synthesis 
while decreasing protein degradation (Heineke & Molkentin, 2006). Cardiac hypertrophy 
is employed to be an adaptive physiologic process, but can develop into a maladaptive 
pathologic process as well. 
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1.2 Physiological Hypertrophy 
Physiological hypertrophy is growth of the heart under physiological or disease-
free conditions. Post-natal heart growth, pregnancy-induced heart growth and exercise-
induced heart growth are all examples of physiological hypertrophy (Bernardo et al., 2010). 
This physiological growth of the heart is associated with normal cardiac structure and 
normal or improved cardiac function (Bernardo et al., 2010). Physiological hypertrophy 
can result in either concentric or eccentric hypertrophy depending on the inciting stimulus 
and physiological situation. Aerobic exercise increases venous return of blood to the heart 
resulting in a volume overload on the heart. As described in the earlier sections above this 
volume overload will lead to chamber dilation/enlargement otherwise known as eccentric 
hypertrophy (Pluim et al., 2000). Static exercise such as weight lifting results in a pressure 
overload leading to wall thickening of the myocardium otherwise known as concentric 
hypertrophy (Bernardo et al., 2010). Metabolically, a heart undergoing physiological 
hypertrophy demonstrates enhanced fatty acid and glucose oxidation to generate ATP 
(Gertz et al., 1988). In regards to cell signalling, the insulin-like growth factor (IGF1)-
phosphoinositide 3-kinase (PI3K)-Akt signalling pathway has been implicated in 
physiological hypertrophy. A study was able to demonstrate that cardiac-specific ablation 
of the IGF1 receptor in mice resulted in the attenuation of the hypertrophic response seen 
in swim-exercised mice compared to the control mice (Kim et al., 2008). In addition Akt, 
the downstream target substrate of phosphoinositide 3-kinase was shown to play a major 
role in physiological hypertrophy but not in pathological hypertrophy. A study 
demonstrated that Akt1 knockout mice—mice which had normal heart sizes in basal 
conditions—showed attenuation of the hypertrophic response in response to swim training 
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compared to control mice. However these Akt1 knockout mice still developed hypertrophy 
in response to pressure overload via transverse aortic constriction (DeBosch et al., 2006)  
 In physiological hypertrophy, the cardiomyocyte grows in length more than it 
grows in width (Heineke & Molkentin, 2006). Thus there is an increase in chamber 
dimension along with a proportional increase in myocardial wall thickness (Heineke & 
Molkentin, 2006). Fibrosis does not exist in physiological hypertrophy because there tends 
to be no cell death. All in all, no cardiac dysfunction results from physiological 
hypertrophy. 
1.3 Pathological Hypertrophy 
Pathological cardiac hypertrophy results from growth of the heart caused by 
disease. Chronic pressure or volume overload leads to myocyte death, fibrotic remodeling 
and a perpetual hypertrophic program that concludes in cardiac dysfunction and heart 
failure (Bernardo et al., 2010), which will be discussed in later sections. Examples of 
pathological conditions that result in chronic pressure or volume overload are hypertension 
and chronic aortic regurgitation respectively (Lorell & Carabello, 2000). In a chronic 
pressure overload condition such hypertension or aortic stenosis, there is unrelenting wall 
stress on the myocardium. In efforts to normalize the wall stress there is an increase in wall 
thickness, otherwise known as concentric hypertrophy. This process differs from 
physiological concentric hypertrophy because the inciting stimulus for pathological 
hypertrophy is usually perpetual and excessive, leading to myocyte death and fibrotic 
replacement, which further compromises the function of the heart (Levy et al., 1990). 
Aortic or mitral regurgitations represent chronic volume overload situations where there is 
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constant accumulation of blood in the heart leading to diastolic wall stress (Grossman et 
al., 1975). This results in ventricular chamber dilation otherwise known as eccentric 
hypertrophy. The feature that differentiates physiological eccentric hypertrophy from 
pathological eccentric hypertrophy is that the inciting stimulus (aortic regurgitation or 
myocardial infarction) persists leading to perpetual chamber dilation and myocyte death 
(Bernardo et al., 2010).  
 The metabolism of the heart during pathological cardiac hypertrophy also differs 
from the metabolism of a physiologically hypertrophied heart. There is a decrease in fatty 
acid oxidation and concomitantly an increase in glucose oxidation relative to the normal 
heart (Vedala et al., 2002). This switch in metabolism may be an energetically favourable 
process employed by the heart with the intention of allowing the heart to produce more 
ATP per molecule of oxygen. 
 There is a multitude of intracellular signalling pathways responsible for activating 
the pathological hypertrophic program. Heterotrimeric G-protein signalling, MAPK 
signalling and calcium signalling are just some of the many pathways that participate in 
the manifestation of pathological hypertrophy (Bernardo et al., 2010). Among calcium 
signalling pathways, calcineurin-NFAT signalling appears to be the major pathway for the 
hypertrophic program. Calcineurin is a phosphatase that dephosphorylates NFAT (Haq et 
al., 2001) allowing for its translocation from the cytoplasm to the nucleus where it 
transcribe specific genes. A study conducted in 2001 was able to demonstrate that 
calcineurin activity was increased in the hypertrophied and failing hearts of human patients 
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(Haq et al., 2001). Another study revealed increases in calcineurin activity in the 
hypertrophied hearts of rodents following aortic banding (Saito et al., 2003). 
As evidenced in figure 1, pathological hypertrophy also differs from physiological 
hypertrophy in morphology. The myocytes grow in width more than they do in length 
(Heineke & Molkentin, 2006). As well there is excessive fibrosis due to the perpetual 
deposition of fibrillary type 1 collagen (Heineke & Molkentin, 2006). 
 
Figure 1: Physiological and pathological types of cardiac hypertrophy. The three 
manifestations of cardiac hypertrophy depending on the inciting stimulus. “ Adapted by 
permission from Macmillan Publishers Ltd: Nature Reviews Molecular Cell Biology 
(Heineke & Molkentin, 2006), copyright 2006. 
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1.4 Heart failure and cardiac hypertrophy 
Heart failure is a syndrome characterized by progressively declining left ventricular 
function leading to inadequate tissue perfusion. This syndrome represents a common final 
course that is subsequent to an initial stressor on the heart. Multiple prospective studies 
have elucidated the primary aetiologies of heart failure. One such study is the Hillingdon 
heart failure population-based study, where the authors categorized 220 new cases of heart 
failure—identified from a population of 151, 000 patients—into different aetiological 
groups based on the medical history of the patient and echocardiographic assessment 
(Cowie et al., 1999). Coronary artery disease, in particular acute myocardial infarction, was 
the single most common aetiology of heart failure making up 36% of cases. Hypertension 
was the second most common primary etiology making up 14% of the 220 new cases 
(Cowie et al., 1999). It is important to note that the 36% of cases attributed to coronary 
artery disease frequently co-existed with a history of hypertension, but the hypertension 
was not independent of the coronary artery disease and was therefore not considered as the 
primary aetiology.  Similar to these findings, the Framingham Heart Study identified 
hypertension and myocardial infarction as the most common attributable risks for 
congestive heart failure (Kannel, 2000). The mechanisms by which these two aetiological 
factors cause heart failure will be discussed.  
 Heart failure constitutes a number of important defining features such as 
cardiomyocyte hypertrophy, systolic and/or diastolic dysfunction and defective 
cardiomyocyte calcium homeostasis (Frey et al., 2004) (Peterson et al., 1978) 
(Beuckelmann et al., 1992). Cardiomyocyte hypertrophy is one of the biological processes 
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that, both precedes and is involved in, the cardiac remodelling process that takes place 
during heart failure. To reiterate, there are two types of cardiac hypertrophy; concentric 
and eccentric hypertrophy. As discussed in previous sections, pressure-overload results in 
concentric hypertrophy and volume overload results in eccentric hypertrophy. Molecularly, 
both phenotypic hypertrophies present with a reversion to the fetal gene program. The re-
installment of this fetal gene program—involving a re-expression and blunting of genes—
modifies the myofilament machinery and energy metabolism of the cardiomyocyte 
(Swynghedauw, 1999). Atrial natriuretic peptide (ANP) and embryonic myosin light chain 
are some of the genes that are re-expressed while genes such as the sarco-endoplasmic 
reticulum calcium ATPase (SERCA) gene are blunted (Swynghedauw, 1999). After a 
myocardial infarction occurs, there is a loss of functional cardiac tissue. As a result there 
is a reduction in regional wall motion and a consequential reduction in stroke volume 
(Pfeffer, 1995). The remaining cardiomyocyte population faces a volume-overload 
(Pfeffer, 1995) because the number of contractile cells capable of handling normal volumes 
of blood is decreased. The volume-overload is also a consequence of sympathetic 
stimulation. The reduction in stroke volume will result in a reduction in blood flow which 
will trigger the sympathetic nervous system to stimulate the juxtaglomerular cells in the 
kidneys. These cells will release renin, an enzyme that will cleave angiotensinogen to 
angiotensin I. Angiotensin I will then be converted to angiotensin II, the effector peptide 
that will constrict the blood vessels and increase sodium and water reabsorption via the 
kidneys (Moon, 2013). Vasoconstriction of the veins and an increased fluid volume 
contribute to an increased preload or volume- overload on the heart (Florea & Cohn, 2014). 
In addition, these cardiomyocytes also face a pressure overload because the remaining 
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cardiomyocytes must now generate a greater amount of pressure to match the systolic blood 
pressure in order to open the aortic valve and subsequently eject blood out of the left 
ventricle. Neurohumoral responses to decreases in blood flow also result in an increased 
afterload, which contributes to the pressure overload. Therefore, the heart displays both a 
dilated ventricular cavity and ventricular wall thickening. This is a compensatory 
hypertrophy in which the heart tries to rescue the reduction in stroke volume by increasing 
both chamber size and the number of force generating units within the myocyte (Pfeffer, 
1995). Yet, unlike the transient and/or intermittent loads that induce cardiac hypertrophy 
in physiological conditions, the increased load on the heart after a myocardial infarction is 
sustained (Lorell & Carabello, 2000). The increased load is further perpetuated by 
compensatory neurohumoral responses that increase systemic blood pressure.  As time 
progresses, this results in decompensatory hypertrophy. To elaborate, the hypertrophy 
actually impairs left ventricular function by weakening the ventricular wall and disrupting 
systolic and diastolic function (Peterson et al., 1978) which ultimately leads to heart failure. 
 Therefore, attenuation of the hypertrophic response subsequent to cardiac damage 
is essential to not only the treatment but the prevention of heart failure. 
1.5 Angiotensin II and cardiac hypertrophy 
Angiotensin II is an octapeptide that exerts vasoconstrictive effects primarily 
through the AT-1 receptor. This peptide is formed through a series of proteolytic cleavages 
in a system call the renin-angiotensin-aldosterone system (Griendling et al., 1993). 
Angiotensinogen, a peptide produced by the liver, is cleaved by renin, a peptide produced 
by the kidneys. This cleavage results in the production of angiotensin I, a decapeptide. 
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Angiotensin I is then cleaved to angiotensin II by an enzyme called angiotensin-converting 
enzyme (Griendling et al., 1993). Angiotensin II circulates in the blood at a concentration 
of 50-100 pmol/L (Moon, 2013). The physiological function of this peptide is to increase 
blood pressure by stimulating contraction of the smooth muscle cells in the vasculature, as 
well as by increasing sodium and water retention (de Gasparo et al., 2000).  
Angiotensin II also has direct hypertrophic effects on the heart. This effect is also 
mediated through the AT-1 receptor. The AT-1 receptor is a seven transmembrane G 
protein-coupled receptor that is coupled to the Gq protein. Intracellular signalling pathways 
such as MAPK (Sadoshima et al., 1995), increased intracellular calcium/protein kinase C 
(PKC) activity (Miyata & Haneda, 1994) and increased leptin autocrine signalling 
(Rajapurohitam et al., 2006) have been shown to be activated once angiotensin II binds to 
its AT-1 receptor. As discussed previously in the sections above, these pathways are 
associated with pathological hypertrophy. Cardiac specific over-expression of the AT-1 
receptor in mice resulted in pathological cardiac hypertrophy and subsequent heart failure 
(Paradis et al., 2000). Another study revealed that mice with a gain of function mutant AT-
1 subtype A receptor displayed cardiac fibrosis and diastolic dysfunction (Billet et al., 
2007).  
The MAPK family consists of a group of serine/threonine kinases that participate 
in the signal transduction for cell growth. When activated, these MAPKs phosphorylate 
nuclear transcription factors such as JUN and MYC, thus activating and allowing these 
transcription factors to regulate the transcription of specific genes (Bernardo et al., 2010). 
These MAPKs are rapidly activated in response to the stimulation of growth receptors. 
These growth receptors are tyrosine kinase receptors which when activated, initiate a chain 
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of tyrosine phosphorylation that will result in the eventual phosphorylation of these 
MAPKs. However G-protein coupled receptors have also been proven capable of activating 
this cascade of tyrosine phosphorylation and MAPK activation. One such receptor is the 
AT-1 receptor. In 1995, a study demonstrated that angiotensin II was able to induce 
tyrosine phosphorylation of many intracellular proteins and able to activate MAPKs 
(Sadoshima et al., 1995). The angiotensin II- induced tyrosine phosphorylation was found 
to be dependent on the increase in intracellular calcium.  
Angiotensin II also increases in intracellular calcium and PKC activity by the Gq 
protein signalling pathway (Mehta & Griendling, 2007). Once angiotensin II binds to the 
AT-1 receptor, the receptor undergoes a conformational change that results in liberation of 
the Gq protein from its heterotrimeric G-protein complex. This protein will then activate 
phospholipase C, an enzyme that will cleave phosphatidyl inositol bisphosphate (PIP2) into 
inositol triphosphate (IP3) and diacylglycerol (DAG). These products will lead to calcium 
liberation from the endoplasmic reticulum and the eventual activation of PKC (Mehta & 
Griendling, 2007).  
One of the downstream targets of PKC is the sodium hydrogen exchanger (NHE-
1), an antiporter located in the plasma membrane that plays a role in regulating intracellular 
pH (Leem et al., 1999). It functions by extruding one proton out of the cell while 
simultaneously bringing in one sodium ion. Thus when proton concentrations exceed 
physiological levels, this antiporter is activated and starts to extrude out protons. At the 
very same instant, it brings in sodium ions thus increasing the intracellular sodium ion 
concentration. An interesting feature of this antiporter is that its sensitivity to proton 
concentrations can be regulated. When PKC is activated, via a Gq dependent mechanism, 
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it phosphorylates NHE-1 thus sensitizing the exchanger to proton concentrations in the cell 
(Karmazyn, 2001). As a result, the exchanger becomes more active at alkaline pHs. Sodium 
concentrations consequently rise resulting in activation of the sodium-calcium exchanger 
(NCX), a transporter that will respond to the increase in sodium by removing it from the 
cell while simultaneously bringing in calcium (Karmazyn et al., 1999). Increases in calcium 
concentrations result in calcium/calmodulin binding, which primes calmodulin to bind to 
calcineurin, a phosphatase that is responsible for dephosphorylating NFAT. NFAT will 
then translocate into the nucleus where it will regulate gene transcription that will induce 
the hypertrophic program. This signalling cascade will be further discussed in upcoming 
sections.  
Angiotensin II has also been shown to increase leptin autocrine signalling. 
Furthermore this increase in leptin signalling has been shown to be critical for angiotensin 
II’s ability to induce hypertrophy (Rajapurohitam et al., 2006). To clarify, this study 
demonstrated that neonatal rat cardiomyocytes treated with angiotensin II exhibited 
hypertrophy, however when a leptin triple mutant receptor antagonist was used in the 
presence of angiotensin II, hypertrophy was abolished (Rajapurohitam et al., 2006). The 
study found that the ability of the leptin antagonist to blunt angiotensin II-induced 
hypertrophy was not due to an interruption in MAPK signalling. In fact the intracellular 
mechanism for this phenomenon is not yet clear (Rajapurohitam et al., 2006). 
1.6 Leptin 
Leptin is a 16 kDa peptide that is the product of the ob gene (Zhang et al., 1994). 
This peptide is most notably recognized as a satiety factor or appetite suppressant, an effect 
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caused by its action on the hypothalamus. Leptin circulates in the blood at physiological 
concentrations of 5-15 ng/mL (Sinha et al., 1996). Leptin plasma levels have been shown 
to correlate with risk of coronary heart disease (Wallace et al., 2001). Adipose tissue is the 
main secretor of leptin (Scherer et al., 1995) although other tissues such as cardiac tissue 
also secrete the hormone (Purdham et al., 2004). Leptin has been shown to directly exert 
hypertrophic effects on isolated neonatal rat cardiomyocytes (Rajapurohitam et al., 2003). 
OB-Ra to OB- Rf represent the 6 isoforms of the leptin receptor through which leptin can 
signal through. However, OB-Rb is distinct from the rest of the five in that structurally it 
is longer than the other 5 isoforms. In addition, functionally, it has full signalling ability 
(Chua et al., 1997). 
Our lab has demonstrated an interesting interaction between angiotensin II and 
leptin in the cardiomyocyte. Angiotensin II induced hypertrophy is abrogated by inhibiting 
the leptin signaling system (Rajapurohitam et al., 2006). To clarify, our lab discovered that 
stimulation of the cardiomyocyte by angiotensin II lead to an increase in leptin secretion 
and thus leptin-autocrine signaling. When a leptin receptor blocker or leptin neutralizing 
antibody was used in the presence of angiotensin II, cardiomyocyte hypertrophy was 
nullified. 
1.7 Fat mass and obesity-associated protein 
The fat-mass and obesity associated protein, abbreviated as FTO, became 
significant in obesity related research after a genome wide association study for type II 
diabetes was conducted in 2007. The researchers were able to find that for the 1924 type II 
diabetes patients they screened, there was a common single nucleotide polymorphism SNP 
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(rs9939609) within the FTO gene on chromosome 16. The strong association between this 
SNP and type II diabetes was later abolished after an adjustment for body mass index 
(BMI) was made, suggesting that the actual correlation existed between the SNP and 
BMI—a risk factor for type II diabetes (Frayling et al., 2007). The study further 
demonstrated with a separate cohort that those who were homozygous for the risk 
allele/SNP (16% of the cohort) had a 1.67 increased odds of obesity and weighed about 3 
kilograms more (Frayling et al., 2007). The FTO SNPs that are showing strong associations 
with BMI exist within the intron of this gene. Thus they may alter the transcription of FTO 
resulting in an altered mRNA transcript and hence an altered FTO translated protein 
(Gerken et al., 2007). 
FTO is a 50 kilodalton peptide that shares sequence motifs with 2-oxoglutarate 
oxygenases (Gerken et al., 2007). 2-oxoglutarate oxygenases exhibit a diverse range of 
functions such as DNA repair and histone lysine demethylation. In vitro assays of a 
recombinant murine FTO protein have revealed the protein’s ability to demethylate methyl-
thymine nucleic acids in single stranded DNA as well as 3-methyl uridine in single stranded 
RNA but with relatively lower efficiency (Gerken et al., 2007). The recombinant murine 
FTO’s activity was dependent on the presence of iron and 2-oxoglutarate. As with other 2-
oxoglutarate oxygenases, the iron serves as a cofactor for the murine recombinant FTO, 
while the 2-oxoglutarate serves as a cosubstrate (Gerken et al., 2007). It is quite plausible 
that given its relevance to obesity, FTO may be regulating the transcription of genes 
necessary for metabolism and energy balance.  FTO mRNA was found to be expressed in 
all murine tissues with the highest expression found in the brain (Gerken et al., 2007). 
Specifically, the arcuate nuclei, paraventricular nuclei, dorsomedial nuclei and 
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ventromedial nuclei of hypothalamus was found to have high levels of FTO mRNA 
transcripts. This was another finding that bolstered the proposition that FTO could be 
involved in energy regulation given that the hypothalamus is the primary center in the brain 
for energy regulation and balance. To further test this proposition, the aforementioned 
study observed FTO mRNA levels in dissected hypothalamic nuclei from three groups of 
mice; freely feeding, 48-hour fasted mice and 48-hour fasted mice with daily 
intraperitoneal injections of leptin. The latter group was included to determine if any 
changes caused by the fasting were mediated by a reduction in circulating levels of leptin. 
The researchers observed that there was a 60% reduction of FTO mRNA in the arcuate 
nucleus of the fasted mice. In addition this reduction was not rescued by leptin 
supplementation (Gerken et al., 2007). Based on this study FTO levels in the hypothalamus 
appear to be nutritionally regulated. Another study has shown that a global knockout of the 
FTO gene in mice results in a lean phenotype (Fischer et al., 2009). These mice exhibit 
growth retardation from post-natal day 2 onwards and an average weight reduction of about 
30-40% six weeks after birth compared to wild-type mice. Magnetic resonance imaging 
showed a 60% reduction and 23% reduction in fat mass of male and female respectively 
when compared to the wild-type. There was a significant reduction in epigonadal white 
adipose tissue with marked decrease in adipocyte size (Fischer et al., 2009). Furthermore, 
the FTO -/- , FTO +/- and FTO +/+ mice were subjected to a 12-week high fat diet. After the 
12 weeks FTO -/- and FTO +/- mice showed a significantly reduced weight compared to FTO 
+/+ mice (Fischer et al., 2009). This lean phenotype was attributed to an increase in the basal 
metabolic activity of the mice as food intake does not differ between the knockout mice 
and the wildtype mice (Fischer et al., 2009).  
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Wang et al. have demonstrated that leptin, a satiety factor involved in regulating 
eating behaviour, downregulates FTO protein expression in the hypothalamus (Wang et 
al., 2011). This study demonstrated this by subjecting mice to energy restriction (60% of 
the ad libitum food consumption) for 8 weeks and 50 weeks. At both time points, FTO 
mRNA transcripts and protein expression had significantly decreased. Conversely, in leptin 
receptor (OB-Rb) deficient mice, db/db, which were also subjected to energy restriction 
for the same time periods mentioned above there was no decrease in either gene or protein 
expression of FTO (Wang et al., 2011). Moreover, arcuate nucleus cultures were treated 
with leptin directly, and a STAT3-dependent FTO downregulation was observed. Thus the 
authors of the study concluded that energy restriction induced-FTO downregulation in the 
hypothalamus was being mediated by leptin-STAT3 signalling (Wang et al., 2011). This 
interaction with leptin, an important metabolic hormone, bolsters the conclusion that FTO 
regulates metabolism and energy expenditure.  
Our lab has dedicated efforts towards trying to elucidate direct mechanisms 
explaining the association between obesity and cardiac disease. We identified leptin as one 
of those direct mechanisms, as leptin levels are significantly elevated in obesity. Moreover 
leptin has been shown to exert hypertrophic effects on the heart via its long-form receptor 
OB-Rb (Rajapurohitam et al., 2003). Given leptin’s STAT3-dependent effect on FTO in 
the hypothalamus demonstrated by Wang in 2011, our lab was interested in assessing FTO 
expression in cardiomyocytes in response to leptin. Our lab has been the first, to not only 
identify FTO in the cardiomyocyte, but also to demonstrate its nuclear localization within 
the cardiomyocyte, a finding that is concordant with FTO’s demethylating functions (Gan 
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et al., 2013). In addition our lab has shown that leptin also regulates FTO protein expression 
in the cardiomyocyte.  
In contrast to the finding of Wang concerning the interaction between leptin and 
FTO in the hypothalamus, our lab has shown that leptin upregulates FTO in the 
cardiomyocyte.  Specifically, leptin binds to OB-Rb and results in the dimerization and 
subsequent translocation of STAT3 into the nucleus. Once in the nucleus, dimerized 
STAT3 activates the protease cathepsin L resulting in the proteolytic cleavage of p 200 
CUX into p 75 and p 110 CUX 1 proteins that are transcription factors. The active 
transcription factor p 110 upregulates the transcription of the FTO gene (Figure 2). 
Moreover, this upregulation is responsible for leptin’s hypertrophic effect on the 
cardiomyocyte. When FTO is silenced using small interfering RNA (siRNA), the 
hypertrophic response of the cardiomyocyte to leptin is abolished (Gan et al., 2013). Thus 
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FTO upregulation in the cardiomyocyte is necessary for leptin-induced cardiomyocyte 
hypertrophy. 
  
1.8 Hypothesis and objectives 
Rationale: In our lab, we study mechanisms that lead to cardiac hypertrophy and 
identify specific probable molecular targets for pharmacological intervention. We have 
identified that leptin, a satiety factor produced in our body induces cardiac hypertrophy. 
Leptin’s hypertrophic effect appears to be mediated through multiple intracellular 
Figure 2: Proposed mechanism for leptin-induced JAK2/STAT3-dependent FTO 
upregulation. Activation of the long form receptor (OB-Rb) results in the dimerization 
and translocation of STAT3 into the nucleus where it activates the protease cathepsin L 
resulting in proteolytic processing of p200 CUX to the shorter p75 and p110 CUX1 
proteins. The latter upregulates FTO resulting in the hypertrophic response (Gan et al., 
2013). 
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signalling pathways. One of these pathways involves an increase in calcineurin activity. 
When calcineurin is inhibited, using calcineurin inhibitor FK506, the leptin-induced 
hypertrophy is abolished (Rajapurohitam et al., 2012). As mentioned previously, FTO 
upregulation also mediates leptin’s hypertrophic effect on the cardiomyocyte. When FTO 
is silenced using siRNA, leptin’s hypertrophic effect is abolished. Thus it appears that FTO 
upregulation and calcineurin activation are necessary molecular events for leptin-induced 
cardiomyocyte hypertrophy. This may suggest that FTO and calcineurin share a common 
pathway. In this current study, we were interested in determining which other hypertrophic 
agonists had the ability to regulate FTO expression in the cardiomyocyte. In the first 
objective of this current study, we observed that angiotensin II was able to significantly 
regulate FTO in the cardiomyocyte. Angiotensin II has been demonstrated to activate the 
NHE-1/calcineurin signalling pathway via the Gq protein signalling pathway, resulting in 
hypertrophy. This bolsters the hypothetical concept that the activation of calcineurin and 
the upregulation of FTO may take place in a common pathway. As well, angiotensin II has 
been demonstrated to increase leptin synthesis and secretion from the cardiomyocyte 
leading to autocrine effects of leptin on the cardiomyocyte. When leptin signaling is 
disrupted in the presence of angiotensin II, angiotensin II induced hypertrophy is 
abrogated. Therefore I have formulated two hypotheses; 1.  Angiotensin II-induced FTO 
upregulation is mediated by NHE-1/calcineurin activation and 2. Angiotensin II-
induced leptin secretion and autocrine signalling leads to FTO upregulation in 
neonatal rat ventricular myocytes. To carry out my investigation of this hypothesis, I have 
created a tentative list of objectives phrased in the form of major questions I sought to 
answer. 
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Objectives for Hypothesis 1: 
a)  Do other hypertrophic agonists (apart from leptin) upregulate FTO?  
 To assess the effects of angiotensin II and phenylephrine on FTO expression 
 To formulate a hypothesis based on the results of the above sub-aim 
b) Does NHE-1 and Calcineurin play a critical role in angiotensin II-induced FTO 
upregulation?  
 To assess the effects of NHE-1 inhibitor, EMD87580, and calcineurin 
inhibitor, FK506, on angiotensin II-induced FTO regulation  
Objectives for Hypothesis 2: 
a) Does angiotensin II increase JAK2-STAT3 signalling  
 To assess jak2-stat3 activation after angiotensin II treatment with or without 
quadruple mutant leptin receptor antagonist 
b) Is angiotensin II-induced FTO upregulation JAK2 dependent?  
 To assess FTO expression after angiotensin II treatment with or without jak2 
inhibitor AG490. 
c) Does angiotensin II- induced FTO upregulation involve leptin signaling? 
 To assess FTO expression after angiotensin II treatment with or without 
quadruple mutant leptin receptor antagonist 
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Chapter 2  
2 Materials and Methods  
 
2.1  Primary culture of rat neonatal ventricular 
cardiomyocytes 
Neonatal hearts were extracted from 1-5 days old Sprague–Dawley rats (Charles River 
Canada, Montreal, Quebec, Canada). After the neonates were sacrificed, hearts were 
isolated and rinsed in buffer containing 1x Hank’s balanced salt solution (HBSS) (Wisent 
Inc., St. Bruno, QC). Hearts were squeezed gently to remove residual blood and transferred 
to another dish containing fresh ice-cold 1x HBSS. Atria were removed and ventricles were 
placed into another dish. Ventricles were minced into smaller pieces using a surgical blade. 
The heart pieces were then transferred into a water-jacketed Erlenmeyer flask maintained 
at 37 °C after which digestion buffer was added for six sequential digestions. The digestion 
buffer contained 10% 10 x HBSS (Gibco, Life Technologies Burlington, ON, Canada), 2% 
1 M HEPES (Gibco), 2% Penicillin/Streptomycin (Gibco), 0.11 mg/ml Collagenase 
(Worthington Corp., Lakewood, NJ, USA), 0.13 mg/ml Trypsin (Worthington) and 
0.03mg/ml DNase II (Worthington).  After each digestion, the supernatant was removed 
from the flask and poured into an Eppendorf tube containing the same volume of stop 
buffer which consisted of 10% 10 x HBSS, 2% Penicillin/streptomycin and 20% Fetal 
Bovine Serum (FBS) to abolish enzyme activity. The solution containing both the 
supernatant and stop buffer was filtered in another Eppendorf tube using a 70 µm cell 
strainer and centrifuged at 514 g at 4°C. The supernatant was discarded and pellets were 
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re-suspended in the cell culture medium. The suspension was subjected to pre-plating for 
one hour followed by another 30 min of pre-plating to ensure cardiomyocyte enrichment. 
Following pre-plating, Primaria™ (Falcon) culture dishes were plated with 
cardiomyocytes at an optimal density, a density dependent on the type of experiment being 
conducted. Cells (1 x 104 cells) were plated to perform cell surface area analysis as this 
quantity ensured sufficient density to visualize growth while 6 x 104 cells were plated for 
RNA and protein isolation as this quantity ensured sufficient density for gene expression 
and protein expression. Cells were counted using Countess Automated Cell Counter (Life 
Technologies Inc, Burlington, Ontario, Canada). The cells were grown in an incubator at 
37 °C 5% CO2. After 48 hours, myocytes were washed with phosphate buffer saline-ABC 
(PBS-ABC) and cultured in serum-free medium for another 24 hours before starting the 
treatments. All the reagents were filtered, sterilized and autoclaved.  
Table 1: Composition of culture medium reagents for neonatal rat cardiomyocytes 
Chemical Name Concentration Manufacturer 
DMEM/F12 1 pkg Gibco 
NaHCO3 2.4 mg/ml Sigma-Aldrich 
Fetal Bovine Serum (FBS) 10 % Gibco 
Hepes 30 mM Gibco 
Bromodeoxyuridine 0.1 mM Sigma-Aldrich 
Linoleic Acid 5 µg/ml Sigma-Aldrich 
Pyruvic Acid 3 mM Sigma-Aldrich 
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Bovine Serum Albumin 
(BSA) 
2 mg/ml Gibco 
Penicillin/Streptomycin 1 % Gibco 
Insulin 10 µg/ml Sigma-Aldrich 
Holo-Transferrin 10 µg/ml Sigma-Aldrich 
Sodium Selenite 10 ng/ml Sigma-Aldrich 
L-Ascorbic Acid 100 µM Gibco 
MEM Non-essential Amino 
Acids 
1 % Sigma-Aldrich 
MEM Vitamins 100X 0.1 % Sigma-Aldrich 
 
Table 2: Composition of PBS-ABC solution for neonatal rat cardiomyocytes. All 
chemicals are from Sigma-Aldrich (Oakville, ON, Canada) 
Reagent  Chemical Concentration 
PBS A NaCl 10 g/L 
KCl 0.250 g/L 
Na2HPO4·7H2O 2.71 g/L 
KH2PO4 0.250 g/L 
PBS B CaCl2·2H2O 1.32 g/L 
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PBS C MgCl2·6H2O 2.13 g/L 
   
PBS ABC PBS A 80 % 
 PBS B 10 % 
 PBS C 10 % 
 
Table 3: Serum-free medium reagents for neonatal rat cardiomyocytes 
Chemical Name Concentration Manufacturer 
DMEM/F12 1 pkg Gibco 
NaHCO3 2.4 mg/ml Sigma-Aldrich 
Bromodeoxyuri
dine 
0.075 mM Sigma-Aldrich 
Bovine Serum 
Albumin (BSA) 
10 mg/ml Gibco 
Penicillin/Strep
tomycin 
1 % Gibco 
Insulin 10 µg/ml Sigma-Aldrich 
Holo-
Transferrin 
5 µg/ml Sigma-Aldrich 
Sodium 10 ng/ml Sigma-Aldrich 
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Selenite 
Fetuin 250 µg/ml Sigma-Aldrich 
CaCl2 80 µg/ml Sigma-Aldrich 
L-Ascorbic 
Acid 
100 µM Gibco 
MEM Non-
essential Amino 
Acids 
1 % Sigma-Aldrich 
MEM Vitamins 
100X 
0.1 % Sigma-Aldrich 
BSA-Palmitate 0.2 % Sigma-Aldrich 
 
2.2 Cell surface area analysis of cardiomyocytes 
Cardiomyocytes were allowed to grow in serum-containing medium for 24 hours. They 
were then washed with PBS-ABC before allowing them to grow again in serum-free 
medium for 24 hours before treatment. Cells were treated with angiotensin II (100 nM), 
phenylephrine (10 M) or leptin (3.1 nM) in the presence or absence of NHE-1 inhibitor 
EMD87580 (5 M), calcineurin inhibitor FK506 (2 nM), Valsartan (10 M), super-ovine 
leptin antagonist (LRA) (100 nM) and JAK2 inhibitor AG490 for 24 hours. For cell surface 
area, the mean of 50 cells were used to provide one value. Cell surface area was analyzed 
using a Leica inverted microscope equipped with an infinity 1 camera at 100 x 
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magnification. Cell surface area was measured using SigmaScan Software (Systat, 
Richmond, CA, USA).    
Table 4: Chemicals used, their concentrations and their manufacturers 
Chemical name Concentration Manufacturer 
Angiotensin II  100 nM Sigma-Aldrich 
Phenylephrine 10 µM Sigma-Aldrich 
Valsartan 10 µM Sigma-Aldrich 
EMD87580 5 µM Merck 
FK506 2 nM Cell Signalling Technology 
LRA  100 nM Protein Laboratories 
Leptin 3.1 nM Sigma-Aldrich 
AG490 50 µM Santa Cruz 
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2.3 RNA isolation and purification 
Following the treatments, total RNA from cells was extracted using TRIzol® Reagent 
(BioRad Laboratories Ltd., Mississauga, ON) according to the manufacturer’s instructions. 
Briefly, following 24 hours of treatment, growth media was removed from cardiomyocytes 
dish and washed with PBS ABC. TRIzol® Reagent was added to each culture dish and 
cells were lysed and homogenized by using a cell scraper. This homogenized sample was 
transferred to small Eppendorf tubes and kept at room temperature for 5 minutes to allow 
complete dissociation of the nucleo-protein complex. Chloroform was added and the tubes 
were shaken vigorously for 15 seconds by hand and incubated at room temperature. This 
mixture was centrifuged at 10,000 g for 30 minutes at 4 °C and separated in 3 phases: lower 
red phenol-chloroform phase, an interphase, and a colourless upper aqueous phase. The 
aqueous phase was removed using a pipette and transferred to a new Eppendorf tube. 
Isopropanol (100%) was added to the aqueous phase and kept overnight at -20 °C. The 
following day, the sample was centrifuged at 10,000 g for 20 minutes at 4 °C. Often, a gel-
like pellet formed on the side and bottom of the tube. This pellet was the RNA. The 
supernatant was discarded from the tube, leaving only the RNA pellet. Ethanol (75%) in 
diethylpyrocarbonate (DEPC) water was added to the tube to wash the RNA. The tube was 
vortexed briefly, then centrifuged at 10,000 g for 20 minutes at 4 °C. Consequently the 
RNA pellet attached to the bottom of the tube, and the supernatant was removed. The pellet 
was air dried for only 10 minutes to prevent loss of solubility. The RNA pellet was 
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dissolved in DEPC treated water. The RNA was quantified using MD SpectraMax M5e 
Reader (Molecular devices, Sunnyvale, CA, USA). 
2.4 First strand cDNA synthesis 
1-5 µg RNA was used to synthesize the first strand of cDNA using Moloney murine 
leukemia virus reverse transcriptase (M-MLV RT) according to the manufacturer’s 
protocol and was used as a template in the polymerase chain reactions (PCR). The cDNA 
synthesis was performed in a nuclease-free micro-centrifuge tube. 1-5 µg of RNA was 
added in the tube followed by DEPC water to make up the volume to 11 L. Then 1x 
random primer and 5 mM deoxynucleoside triphosphates (dNTP) mix was added to the 
same tube. This mixture was heated to 65 °C for 5 minutes and quickly chilled on ice. After 
brief centrifugation, the contents of the tube were collected and 5x first strand buffer, 0.1 
M DTT and M-MLV RT were added and mixed gently up and down using a pipette. The 
tube was incubated at 25 °C for 10 minutes followed by 37 °C for 50 minutes followed by 
termination of the reaction by heating it to 70 °C for 15 minutes. All the reagents were 
from Invitrogen, Life Technologies Inc, Burlington, ON, Canada.  
Table 5: Mixture composition for reverse transcription 
Component Volume/reaction (μL) 
1x Random Primer 1 
5mM dNTP mix 2 
5x First Stand Buffer (FSB) 4 
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0.1M DTT 2 
MLV-RT 1 
 
2.5 Quantitative real-time PCR 
The expression of the genes was performed in 10 µl reaction volumes using EvaGreen 
qPCR Mastermix (Applied Biological Materials Inc., Richmond, BC, Canada) and 
fluorescence was measured and quantified using CFX96 Touch™ Real-Time PCR 
Detection System (BioRad Laboratories Ltd., Mississauga, ON, Canada). The Real-Time 
PCR reaction was carried out in 96 well plates from Bio-Rad and each well contained 10 
µl mixture of components. PCR entailed amplification of gene for 35-40 cycles with 
temperature changes. The PCR reaction steps consists of the initiation step (heating the 
samples at 95 °C for 3 minutes), denaturation step (samples are heated at 95 °C for 30 
seconds as this step separates DNA templates by disrupting the hydrogen bonds thus 
producing single-stranded DNA), annealing step (samples are cooled to 50-60 °C for 20 
seconds which results in primers binding to the single-stranded DNA) and elongation step 
(samples are heated at 72 °C so that the Taq polymerase enzyme synthesizes a new 
complementary DNA strand). The primer sequences used for 18s, ANP, α-skeletal actin, 
FTO, CUX1, Cathepsin L and MCIP are shown in table 7. 18S mRNA expression was used 
as a control. 
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Table 6: Real Time PCR reaction mixture 
Component Volume/reaction (μL) 
EvaGreen qPCR Mastermix 5 
Forward Primer 0.5 
Reverse Primer 0.5 
cDNA 2 
Double Distilled Water 2 
 
Table 7: Primer sequences and Real Time PCR conditions 
Primers PCR parameters 
Phase Temperature in 
oC  
18s 
Forward: 
5’-GTATCCCGTTGAACCCCATT-3’ 
Reverse:  
5’-CCATCCAATCGGTAGTAGCG-3’ 
Denaturation 
Annealing 
Extension 
95 
58 
72 
ANP 
Forward:  
Denaturation 
Annealing 
95 
58 
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5’-CTGCTAGACCACCTGGAGGA-3’ 
Reverse:  
5’-AAGCTGTTGCAGCCTAGTCC-3’ 
Extension 72 
α-skeletal actin 
Forward:  
5′-CACGGCATTATCACCAACTG-3′ 
Reverse:  
5′-CCGGAGGCATAGAGAGACAG-3′ 
Denaturation 
Annealing 
Extension 
95 
58 
72 
FTO 
Forward:  
5’- AGGGCTGCACCATCAATTAC-3’ 
Reverse:  
5’- TCACGTTGTAGGCTGCTCTG-3’ 
Denaturation 
Annealing 
Extension 
95 
58 
72 
MCIP 
Forward:  
5’-GCCCAATCCAGACAAACAGT -3’ 
Reverse:  
5’-TGATTTTTGGCTTGGGTCTC -3’ 
Denaturation 
Annealing 
Extension 
95 
58 
72 
Cathepsin L Denaturation 95 
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Forward:  
5’-GAGAGCAGTGTGGGAGAAGA-3’ 
Reverse:  
5’-ATCTGCAGCATCAGAGGTTC-3’ 
Annealing 
Extension 
58 
72 
CUX1 
Forward:  
5’-GGAGGAAGCTGAGCACAAAC-3’ 
Reverse:  
5’-GAGGCCAGTTGGAGAGAGTG-3’ 
Denaturation 
Annealing 
Extension 
95 
58 
72 
 
2.6 Western Blotting 
Cells were treated with appropriate compounds and washed with cold PBS. PBS was 
discarded completely without drying the cells and lysis buffer containing various 
compounds and protease inhibitors were added. The cells were scraped using a dish scraper 
and transferred into small tubes which were then kept on ice. The lysates were pipetted 
several times to ensure complete breakage of the cells in the buffer. The tubes were 
centrifuged at 10,000 g for 10 minutes. The solution had two forms: clear solution at the 
top and pellets at the bottom. Clear solution was removed and transferred to other small 
tubes leaving the pellets in the tube. This clear solution was transferred to the 48-well plate 
and then appropriate Bio-Rad protein essay solution was added. Following the addition of 
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protein assay, plates were read for absorbance at 595 nm and the amount of protein was 
determined using a BSA standard curve. 30 to 50 µg of protein was used to prepare samples 
and 6x sample buffer containing -mercaptoethanol (1:10 dilution) was added. These 
samples were heated at 100 °C for 10 minutes. Then sodium dodecyl sulfate (SDS) 
containing polyacrylamide gels were prepared. 10% gels were made.   
Gels were transferred into the box and the box was filled with 1x Running Buffer. Samples 
were loaded into the wells of the gel and 9 µL protein marker (Bio-Rad) was loaded in one 
well. The whole box was connected to the power source and a constant 100 mV electric 
current was provided. The proteins were then separated according to their molecular 
weights on to the gels; high molecular weight proteins were separated at the top of the gel 
and low molecular weight protein remained at the bottom of the gel. Electric current was 
stopped and the gels were transferred on to the cassette sandwich containing sponge, filter 
paper, nitrocellulose membrane (0.45 µm), gel, filter paper and sponge.   
This sandwich was then transferred to another box and filled with 1x Transfer Buffer which 
was then connected to a power unit. Constant 30 mA electric current was provided and the 
whole assembly was placed at 4 °C room temperature for overnight transfer. The following 
day, membranes were removed, transferred to the box and the membranes were stained 
with Ponceau S solution to check transfer efficiency and protein quality. Following the 
staining, Ponceau S solution was discarded and membranes were washed with 1x Wash 
Buffer three times for 10 minutes each to remove residue from the solution completely. 
Membranes were blocked with 5% skim dry milk solution for 1 hour at room temperature 
on a plate shaker. The milk solution was discarded and the membranes were washed with 
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wash buffer three times for 10 minutes each to remove the residue of the milk solution and 
then these membranes were probed with the primary antibody of FTO, -actin NFAT3, 
PCNA, P-JAK2, JAK2, P-STAT3, STAT3. The boxes were kept on the shaker overnight 
at 4 °C. The following day, the membranes were kept on a shaker for one hour at room 
temperature. The membranes were then washed with wash buffer three times for 10 
minutes each to remove the primary antibody completely from the membrane and proper 
secondary antibodies (goat-anti-mouse, goat-anti-rabbit and donkey-anti-goat) were added. 
The boxes were kept on the shaker for one hour. After one hour the membranes were 
washed again with wash buffer three times. The membranes were then read using Odyssey 
Clx Infrared Imaging System (Li-COR) (Lincoln, NE, United States). The blots were 
analyzed using FluorChem 8000 software. Due to the use of different software for the 
imaging of the blots and the quantification of the blots, the densitometric measurements 
may not exactly reflect the density of the blots seen in the images. 
Table 8: Composition of lysis buffer 
Chemical  Concentration Gm/ml 
Tris-HCl 50 mM 1.212 
NaCl 150 mM 1.740 
Triton 1% 2 ml 
Glycerol 10% 20 ml 
EDTA 2 mM 0.117 
EGTA 2 mM 0.152 
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NaF 50 mM 0.42 
Na3Vo4 200 µM 0.0072 
Na4P2O7 10 mM 0.892 
β-Glycerophosphate 40 mM 1.782 
 
Table 9: Composition of buffers used in western blotting. The pH was adjusted to 7.5 
Chemical Running 
Buffer 
 Transfer 
Buffer 
 Wash Buffer 
Tris base 3 gm  3 gm  3 gm 
Glycine 14.4 gm  14.4 gm  --- 
SDS 1gm  ---  --- 
NaCl ---  ---  9 gm 
Tween20 ---  ---  1 ml 
Methanol ---  200 ml  --- 
Water 1 liter  800 ml  1 liter 
 
Table 10: Details of antibodies, dilution ranges, types and manufacturers 
Antibody Dilution range Type Manufacturer 
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NFAT3 1:500 Rabbit polyclonal Santa-cruz 
FTO 1:500 Mouse monoclonal Abcam 
p-JAK2 1:500 Goat polyclonal Santa-cruz 
JAK2 1:500 Mouse monoclonal Santa-cruz 
p-STAT3 1:1000 Rabbit polyclonal Cell signalling 
STAT3 1:1000 Rabbit polyclonal Santa-cruz 
β-Actin 1:1000 Goat polyclonal Santa-cruz  
PCNA 1:500 Mouse monoclonal Santa-cruz 
 
2.7 Immunofluorescence 
Cardiomyocytes were grown on collagen-pre-coated glass coverslips in medium. 
Following 24 hour incubation with treatments, cells were fixed in 20:80 acetone: methanol 
for 20 min at 4°C. After 5 minutes of permeabilization in 0.3% Triton X-100 PBS, 
myocytes were blocked for 1 h in 1% BSA in PBS A buffer solution and then incubated 
overnight with the primary antibody against  FTO (1:50 dilution) 1% BSA in PBS A buffer, 
then for 1 hour with a secondary antibody (goat anti-mouse). Nuclei were counterstained 
with the nuclear stain Hoechst 33342 (1 mg/ml, SigmaAldrich) for 5 minutes. 
Cardiomyocytes were visualized using an Olympus IX81 inverted fluorescence 
microscope (Olympus, Shinjuku Tokyo, Japan) and quantification performed using 
SigmaScan Pro v.5 software (Systat Software Inc., San Jose, CA, USA). Due to the use of 
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different software for the imaging of the cells and quantification of the fluorescence, the 
fluorescent measurements may not exactly reflect the fluorescence intensity seen in the 
images. 
2.8 Statistical analysis 
All the experiments were analyzed using GraphPad Prism 6. All data are represented as 
mean ± standard error mean (SEM).  
Data for cell surface area, gene expression, protein expression and immunofluorescence 
were analyzed using one-way analysis of variance (ANOVA) followed by a post hoc Tukey 
test. 
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Chapter 3  
3  Results  
 
3.1 Angiotensin II and phenylephrine induces 
cardiomyocyte hypertrophy 
As evident from Figure 3A and 3B, both phenylephrine and angiotensin II treatments result 
in hypertrophic responses from neonatal rat cardiomyocytes. Phenylephrine treatment 
resulted in an increase in cell surface area (Figure 3A) and an increase in ANP gene 
expression (P < 0.05) (Figure 3B). Angiotensin II treatment also resulted in an increase in 
cell surface area and an increase in ANP gene expression (P < 0.05). 
Figure 3: Angiotensin II & phenylephrine induce cardiomyocyte hypertrophy. Panel 
A displays the quantified assessment for cell surface area of neonatal rat cardiomyocytes 
after 24 h treatment with phenylephrine (PE) or angiotensin II (ANG II). Panel B displays 
fetal gene atrial natriuretic peptide (ANP) expression after 24 h treatment with PE or ANG 
II. Cell surface area and ANP gene expression data are presented as mean ± SEM. (n=8). 
*p<0.05 from control (CON) group. 
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3.2 Angiotensin II upregulates FTO in the cardiomyocyte 
Only angiotensin II displays the ability to significantly increase the expression of FTO, 
demonstrating an increase in FTO gene expression (Figure 4A) (P < 0.05) and an increase 
in FTO protein expression (Figure 4B) (P < 0.05). Phenylephrine did not significantly 
increase FTO expression. 
 
Figure 4: Angiotensin II upregulates FTO in the cardiomyocyte. Panel A displays 
FTO gene expression after 24 hour treatment with phenylephrine (PE) or angiotensin II. 
Panel B displays FTO protein expression after 24 hour treatment with phenylephrine or 
angiotensin II. FTO gene expression and FTO protein expression data are presented as 
mean ± SEM (n=5-8). *p<0.05 from CON group. 
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3.3 Angiotensin II-induced hypertrophy is attenuated by AT-
1 receptor antagonist valsartan, NHE-1 inhibitor 
EMD87580 and calcineurin inhibitor FK506 
As evident from Figure 5A and 5B the hypertrophic effect of angiotensin II is attenuated 
by AT-1 receptor antagonist valsartan, NHE-1 inhibitor EMD87580 and calcineurin 
inhibitor (FK506). Specifically, in panel A, angiotensin II significantly increases cell 
surface area, which is normalized back to control levels by the AT-1 receptor antagonist 
valsartan, the NHE-1 inhibitor EMD87580 and the calcineurin inhibitor FK506 (P<0.05). 
In panel B, alpha-skeletal actin gene expression, which is also significantly increased by 
angiotensin II is also normalized back to control levels by valsartan, EMD87580 and 
calcineurin inhibitor FK506 (P<0.05). 
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Figure 5: Angiotensin II-induced hypertrophy is attenuated by valsartan, EMD87580 
and FK506. Panel A displays cell surface area of cardiomyocyte with ANG II and/or AT-
1 receptor blocker valsartan (VAL) and/or NHE-1 inhibitor EMD87580 (EMD) and/or 
calcineurin inhibitor (FK506). Panel B displays α-skeletal actin gene expression in the 
cardiomyocyte with the same treatments mentioned above. Cell surface area and α-skeletal 
actin gene expression data are presented as mean ± SEM (n=6-8). *p<0.05 from CON 
group. #p<0.05 from ANG II group. 
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3.4 Angiotensin II-induced FTO upregulation is attenuated 
by valsartan, EMD87580 and FK506 
The ability of angiotensin II to increase FTO levels in neonatal rat cardiomyocytes is 
significantly attenuated by valsartan, EMD87580 and FK506. As evident in Figure 6A, 
the increase in FTO gene expression is abolished by all the three agents mentioned above 
(P<0.05). In addition, as seen in Figure 6B, increase in FTO protein expression is also 
abolished by all the three agents mentioned above (P<0.05).  
 Figure 7 (A, B, C) reiterates the effect of these three agents on angiotensin II- 
induced FTO upregulation through immunofluorescence. Angiotensin II demonstrated a 
significant increase in nuclear fluorescence intensity that was attenuated by valsartan, 
EMD87580 and FK506 (P<0.05). 
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Figure 6: Angiotensin II-induced FTO upregulation is attenuated by valsartan, 
EMD87580 and FK506. FTO gene expression (A) and western blot with respective 
quantitative analysis of FTO protein expression (B) data in response to 24 h treatments of 
neonatal rat cardiomyocytes with ANG II and/or VAL and/or EMD and/or FK506. 
Quantitative data presented as mean ± SEM (n=6-8). *p<0.05 from CON group. #p<0.05 
from ANG II group 
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CON ANG II ANG II + VAL VAL 
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CON ANG II ANG II +EMD EMD 
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Figure 7: Nuclear fluorescence images of FTO in fixed cardiomyocytes and 
respective quantitative analysis. Nuclear fluorescence of FTO in the cardiomyocyte 
treated with ANG II and/or VAL (A) and/or EMD (B) and/or FK506 (C) and respective 
quantitative analysis (200 ms exposure time). Quantitative data presented as mean ± SEM 
(n=3). *p<0.05 from CON group. #p<0.05 from ANG II group. 
CON ANG II ANG II + FK506 FK506 
   
48 
 
3.5 Evidence of NHE-1/calcineurin activation 
Figure 8 displays MCIP gene expression data in response to the treatment groups discussed 
above. Angiotensin II significantly increases MCIP expression. This is evidence of 
angiotensin II’s ability to activate calcineurin. This effect is attenuated by valsartan, 
EMD87580 and FK506 (P<0.05). 
As evident in Figure 9, angiotensin II also significantly increases NFAT 3 translocation 
to the nucleus after 24 h treatment. This translocation is abolished by FK506 (P<0.05). 
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Figure 8: Evidence of calcineurin activation; Modulatory Calcineurin Interacting 
Protein (MCIP). MCIP gene expression in response to 24 h treatments cardiomyocytes 
with ANG II and/or VAL and/or EMD and/or FK506. MCIP gene expression data are 
presented as mean ± SEM (n=6). *p<0.05 from CON group. #p<0.05 from ANG II 
group. 
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Figure 9: Evidence of calcineurin activation; Nuclear Factor of Activated T-cells 
isoform 3 (NFAT3). Western blot and respective quantitative analysis of NFAT3 
translocation to the nucleus after 24 h treatment with ANG II and/or FK506. NFAT3 
protein expression gene expression data are presented as mean ± SEM (n=3). *p<0.05 from 
CON group. #p<0.05 from ANG II group. 
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3.6 Angiotensin II-induced hypertrophy is attenuated by 
super-ovine leptin receptor antagonist (LRA) 
Angiotensin II-induced hypertrophy is significantly attenuated by the super-ovine leptin 
receptor antagonist (LRA). The significant increase in cell surface area (Figure 10A) and 
-skeletal actin gene expression (Figure 10B) caused by angiotensin II is attenuated by 
the leptin receptor antagonist (P<0.05). 
 
 
 
Figure 10: Angiotensin II-induced hypertrophy is attenuated by LRA. Panel A 
displays cell surface area of cardiomyocyte with ANG II and/or LRA 24 h treatment. Panel 
B displays α-skeletal actin gene expression after 24h treatment with ANG II and/or LRA. 
Cell surface area and α-skeletal actin gene expression data are presented as mean ± SEM 
(n=5-8). *p<0.05 from CON group. #p<0.05 from ANG II group. 
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3.7 Angiotensin II-induced FTO upregulation is attenuated 
by LRA 
LRA was also able to attenuate angiotensin II-induced FTO upregulation. As evidenced 
in Figure 9C and 9D, angiotensin II-induced FTO upregulation is attenuated by LRA 
(P<0.05). Attenuation of cathepsin L and CUX1 gene expression increases by LRA was 
also observed (P<0.05). 
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Figure 11: Angiotensin II-induced FTO upregulation is attenuated by LRA. Panels A 
and B displays cathepsin L gene expression and CUX1 gene expression respectively after 
ANG II and/or LRA 24 h treatment. Panels C and D displays FTO gene and protein 
expression respectively after ANG II and/or LRA 24 h treatment. FTO gene and protein 
expression data, cathepsin L and CUX1 gene expression data are presented as mean ± SEM 
(n=6-7). *p<0.05 from CON group. #p<0.05 from ANG II group. 
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3.8 Angiotensin II activates JAK2 and STAT3 
As demonstrated in Figure 12, JAK2 is significantly phosphorylated after 15 minutes of 
angiotensin II treatment (P<0.05). In Figure 13 we observe that STAT3 is significantly 
activated after 60 minutes of angiotensin II treatment (P<0.05). 
 
 
 
 
 
 
 
 
 
 
 
  
  
Figure 12: Angiotensin II activates JAK2. Time course of JAK2 phosphorylation after 
ANG II treatment at 0 minutes (m), 5 m, 15 m, 60 m, and 24 hours (H). Quantitative data 
presented as mean ± SEM. *p<0.05 from 0 time point (n=5). 
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Figure 13: Angiotensin II activates STAT3. Time course of STAT3 phosphorylation 
after ANG II treatment at 0 m, 5 m, 15 m, 60 m, and 24 H. Quantitative data presented as 
mean ± SEM. *p<0.05 from 0 time point (n=5).  
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3.9 Inhibition of JAK2 attenuates angiotensin II-induced 
hypertrophy 
Angiotensin II significantly increased cell surface area. This significant increase was 
abolished by JAK2 inhibitor AG490 (P<0.05). In addition the significant increase in α-
skeletal actin caused by angiotensin II was also abolished by AG490 (P<0.05). 
 
  
Figure 14: Angiotensin II-induced hypertrophy is attenuated by AG490. Panel A 
displays cell surface area of cardiomyocyte with ANG II and/or AG490 24 h treatment. 
Panel B displays α-skeletal actin gene expression after 24 h treatment with ANG II and/or 
AG490. Cell surface area and α-skeletal actin gene expression data are presented as mean 
± SEM (n=5-6). *p<0.05 from CON group. #p<0.05 from ANG II group. 
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3.10 Inhibition of JAK2 attenuates angiotensin-II induced 
FTO upregulation 
Angiotensin II-induced increases in CUX1 and cathepsin L gene expression are 
significantly attenuated by JAK2 inhibitor AG490 (Figure A, B) (P<0.05). Moreover, 
angiotensin II induced increases in FTO expression are also significantly attenuated by 
JAK2 inhibitor AG490 (Figure 14 C, D) (P<0.05). 
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Figure 15: Inhibition of JAK2 attenuates angiotensin II-induced FTO upregulation. 
Panel A and B displays cathepsin L and CUX1 gene expression respectively after ANG II 
and/or AG490 24 h treatment. Panel C and D displays FTO gene and protein expression 
respectively after (ANG II) and/or AG490 24 h treatment. FTO gene and protein expression 
data, cathepsin L and CUX1 gene expression data are presented as mean ± SEM (n=6-7). 
*p<0.05 from CON group. #p<0.05 from ANG II group. 
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3.11 Leptin-induced cardiomyocyte hypertrophy is 
attenuated by calcineurin inhibitor FK506 but not NHE-1 
inhibitor EMD87580 
Leptin treatment for 24 h was able to significantly induce cardiomyocyte hypertrophy. As 
evidenced in Figure 16A and 16B, compound FK506 was able to significantly attenuate 
increases in cell surface area and -skeletal actin gene expression respectively (P<0.05). 
However, as evidenced by Figure 16C and 16D inhibition of the sodium hydrogen 
exchanger proved not to affect the hypertrophic response to leptin (P<0.05). 
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Figure 16: Leptin-induced hypertrophy is attenuated by FK506. Panels A and B 
displays cell surface area and α-skeletal actin gene expression of cardiomyocyte after 24 
h leptin (LEP) and/or LRA and/or FK506 treatment. Panels C and D displays cell surface 
area and α-skeletal actin gene expression of cardiomyocyte with after 24 h LEP and/or 
LRA and/or EMD treatment. Cell surface area and α-skeletal actin gene expression data 
are presented as mean ± SEM (n=6). *p<0.05 from CON group. #p<0.05 from LEP 
group. 
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3.12 Leptin-induced FTO upregulation is attenuated by 
FK506 but not EMD87580 
As evidenced in Figure 17 leptin-induced FTO upregulation was attenuated by LRA 
(P<0.05). However, only the calcineurin inhibitor FK506 was able to significantly blunt 
the upregulation of FTO caused by leptin treatment (Figure 17 A, B) (P<0.05). NHE-1 
inhibitor, EMD87580, was unable to attenuate the upregulation of FTO caused by leptin. 
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Figure 17: Leptin-induced FTO upregulation is attenuated by FK506. Panels A and 
B display FTO gene and protein expression respectively after 24 h leptin and/or LRA 
and/or FK506 treatment. Panels C and D displays FTO gene and protein expression 
respectively after 24 h leptin and/or LRA and/or EMD87580 treatment. Cell surface area 
and α-skeletal actin gene expression data are presented as mean ± SEM (n=6). *p<0.05 
from CON group (n=6). #p<0.05 from LEP group. 
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Chapter 4  
4 Discussion  
Cardiovascular disease stands as one of the leading causes of death nationwide. Hospital 
discharges for heart failure and other cardiovascular diseases have been steadily increasing 
for more than 2 decades (Roger et al., 2011) . This trend is ironically a product of 
advancements in cardiovascular medicine and increased longevity (McMurray & Pfeffer, 
2005). As the country faces an increase in an aging demographic, heart failure is an 
inevitable burden the health care system will have to deal with. One of the main features 
of heart failure is cardiac hypertrophy. Hypertrophy initially acts as a compensatory 
mechanism to relieve the stress placed on the heart due to the extra workload that occurs 
in heart failure. Unfortunately, the perpetual stress causes the heart to transition into 
decompensatory hypertrophy (Pfeffer, 1995) in which the growth becomes maladaptive 
and deleterious to the heart’s function. In this decompensatory stage, left ventricular 
function progressively declines leading to inadequate tissue perfusion. 
 In heart failure neurohumoral systems are upregulated. One of these systems is 
called the renin-angiotensin-aldosterone system in which angiotensin II is the main effector 
of this system (Griendling et al., 1993). This system is upregulated in order to promote 
vasoconstriction and fluid reabsorption, which will result in an increased venous return to 
the heart thus restoring stroke volume. However, angiotensin II has a direct pathological 
hypertrophic effect on the heart (Paradis et al., 2000). Perpetual stimulation of the heart by 
angiotensin II activates intracellular pathways such as MAPK (Sadoshima et al., 1995) and 
NHE-1/calcineurin (Karmazyn et al., 1999) that will result in pathological hypertrophy.  
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Obesity is a disease that is also associated with many cardiovascular diseases such 
as hypertension and cardiac hypertrophy (Kenchaiah et al., 2002). Our lab has looked at 
potential causal links between obesity and cardiovascular disease. One such link is the 
hormone leptin, a hormone that is increased in circulation during obesity due to an increase 
in adipose tissue, the main site of leptin production (Zhang et al., 1994). Our lab has 
demonstrated that leptin induces cardiac hypertrophy (Rajapurohitam et al., 2003). One of 
those signalling pathways in which leptin induces hypertrophy is through the upregulation 
of the fat mass and obesity associated protein (FTO) (Gan et al., 2013). Through this 
aforementioned study, our lab has been able to characterize FTO as a hypertrophic protein 
in the cardiomyocyte. Thus the presumption is that other myocardial hypertrophic agonists 
such as angiotensin II may also upregulate FTO. 
Pathological cardiac hypertrophy is a prominent feature of heart failure. Factors 
such as angiotensin II that induce pathological hypertrophy are factors that must be studied 
in depth. More importantly, the signalling pathways through which they induce 
hypertrophy must be elucidated such that proper pharmacological interventions can be 
formulated. Thus in this study—using neonatal rat ventricular cardiomyocytes—we used a 
series of in vitro experiments to determine the signalling mechanisms behind angiotensin 
II-induced hypertrophy in relation FTO expression. 
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4.1 Angiotensin II and phenylephrine induce cardiomyocyte 
hypertrophy 
Angiotensin II and phenylephrine are the agonists we chose to assess hypertrophy 
and FTO expression in the cardiomyocyte. Studies, including those from our laboratory, 
have shown that 100 nM concentration of angiotensin II (Nakamura et al., 1998; 
Rajapurohitam et al., 2006) and 10 M concentration of phenylephrine (Gan et al., 2005; 
Omura et al., 2002) significantly induces hypertrophy in neonatal rat cardiomyocytes. Our 
results show that angiotensin II and phenylephrine significantly increase cell surface area 
and atrial natriuretic peptide gene expression. 
4.2 Angiotensin II induces FTO upregulation in the 
cardiomyocyte 
Only 24 h treatment with angiotensin II was able to significantly upregulate FTO 
in the cardiomyocyte as evidenced by gene expression and protein expression. This 
phenomenon was interesting because although angiotensin II and phenylephrine act 
through different receptors, their receptors signal through the same Gq protein (Dorn & 
Brown, 1999) and activate the same intracellular signalling pathways that induce 
hypertrophy. One reason for the apparent difference in ability to upregulate FTO between 
the two agonists may be their difference in the extent to which they activate the Gq protein 
signalling pathway. One study demonstrates that angiotensin II, through the AT-1 receptor, 
is able to increase the Na+/Ca2+ exchanger (NCX) activity to a greater degree than 
phenylephrine in the cardiomyocyte via a Gq dependent mechanism (Ballard & Schaffer, 
1996). Angiotensin II was able to increase the exchanger’s activity to 125%, while 
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phenylephrine only increased it to 111%. Although the disparity between the activity levels 
may not be significant, it is important to note that a 100 M phenylephrine concentration 
was used to achieve maximal stimulation. Conversely, a 5 nM angiotensin II concentration 
was used to achieve maximal stimulation. Thus it appears that the NCX activity is much 
more sensitive to angiotensin II. Both angiotensin II and phenylephrine had their effect on 
the exchanger abolished when a protein kinase C inhibitor was used bolstering the 
conclusion their effect on the exchanger was Gq-phospholipase C-mediated (Ballard & 
Schaffer, 1996).  
Our lab has shown that leptin increases FTO via a JAK2/STAT3 dependent 
mechanism (Gan et al., 2013). Interestingly enough, this may also explain angiotensin II’s 
ability to upregulate FTO as opposed to phenylephrine’s inability to upregulate FTO. We 
have demonstrated that angiotensin II’s hypertrophic effect on the cardiomyocyte is 
mediated through leptin signalling in this current study and in past studies (Rajapurohitam 
et al., 2006). To elaborate, angiotensin II was shown to increase leptin synthesis and OB-
Rb receptor synthesis in the cardiomyocyte thus increasing leptin autocrine signalling 
(Rajapurohitam et al., 2006) . Leptin receptor antagonists and leptin neutralizing antibodies 
were able to abolish angiotensin II-induced hypertrophy (Rajapurohitam et al., 2006). 
Based on this evidence, it is conceivable the angiotensin II is upregulating the leptin system 
which is, in turn, upregulating FTO via the autocrine effects of leptin. 
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4.3 NHE-1 and calcineurin play critical roles in angiotensin 
II-induced cardiomyocyte hypertrophy 
NHE-1’s primary role is to extrude out acid from the cell when pH levels begin to 
drop as a result of processes such as lactate production or even in pathological conditions 
such as ischemia (Leem et al., 1999). While extruding out protons, the transporter 
simultaneously brings in the same number of sodium ions. This 12 transmembrane domain 
transporter contains phosphorylation sites near the carboxyl terminus (Counillon & 
Pouysségur, 1995) (Karmazyn et al., 1999). When phosphorylated, the exchanger becomes 
sensitized to proton concentrations. Thus it’s activity level is greater at a more alkaline pH 
(Karmazyn, 2001). 
Angiotensin II is able to induce phosphorylation of NHE-1 through a Gq dependent 
PKC activation (Mehta & Griendling, 2007). The increased activity of NHE-1 will result 
in intracellular sodium accumulation. This will in turn affect the NCX exchanger by 
affecting it’s sodium/calcium concentration gradients (Karmazyn, 2001). The end result is 
an intracellular accumulation of calcium that results in activation of the calcineurin/NFAT 
signalling pathway culminating in the induction of the hypertrophic program (Ennis et al., 
2007). 
In this study, a specific NHE-1 inhibitor EMD87580, was able to attenuate 
angiotensin II-induced cardiomyocyte hypertrophy as evidenced by attenuation of 
angiotensin II-induced increases in cell surface area and α-skeletal actin. In one study that 
supports this finding, the NHE-1 inhibitor HOE 694 was able to significantly attenuate 
phenylephrine induced protein synthesis in ventricular cardiomyocytes (Schlüter et al., 
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1998). In another study, the NHE-1 inhibitor EMD87580  attenuated aldosterone-induced 
increases in cell surface area and atrial natriuretic peptide (ANP) (Karmazyn et al., 2003). 
 In the current study calcineurin inhibitor FK506, was also able to attenuate 
angiotensin II-induced hypertrophy. Other studies have also demonstrated the ability of 
FK506 to interrupt the hypertrophic process. For example, our lab has demonstrated this 
compound’s ability to attenuate leptin-induced cardiomyocyte hypertrophy 
(Rajapurohitam et al., 2012). 
4.4 NHE-1 and calcineurin play critical roles in AT-1 
mediated angiotensin II-induced FTO upregulation 
NHE-1 inhibitor EMD87580 and calcineurin inhibitor FK506 significantly 
attenuated FTO expression. This was evidenced by gene as well as protein expression. This 
was further demonstrated in immunofluorescence experiments. Nuclear fluorescence 
intensity was significantly increased by 24 h treatment of angiotensin II in fixed cells. 
Valsartan, EMD87580 and FK506 all returned FTO fluorescence intensity back to basal 
levels. Thus it appears that the NHE-1/calcineurin pathway is a hypertrophic signalling 
mechanism that is critical for regulating the expression of FTO, a protein that has been 
shown to be hypertrophic in the heart. 
4.5 Evidence of calcineurin activation 
Modulatory calcineurin interacting protein (MCIP) is often used as a marker of 
calcineurin activation. It is upregulated after calcineurin signalling and, in a negative 
feedback loop, binds to calcineurin to suppress its activity (Molkentin et al., 1998). 
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However MCIP appears to have a dual effect on calcineurin. One study assessed MCIP 
knockout mice and their response to a constitutively expressed calcineurin transgene (Vega 
et al., 2003). These mice had an exacerbated hypertrophic response, agreeing with the 
notion that MCIP serves to suppress calcineurin activity. However, in this same study, 
MCIP knockout mice were subjected to chronic adrenergic stimulation or pressure 
overload but were unable to develop hypertrophy in both situations demonstrating that 
MCIP is necessary for the facilitation of hypertrophy (Vega et al., 2003). 
In this current study, angiotensin II significantly increased MCIP gene expression. 
The increase was attenuated by AT-1 receptor antagonist valsartan, NHE-1 inhibitor 
EMD87580 and calcineurin inhibitor FK506. This finding is supported by one study which 
also demonstrated angiotensin II’s ability to increase MCIP gene expression in the 
cardiomyocyte. This increase was attenuated by a novel chimeric natriuretic peptide, a 
protein proposed to inhibit NHE-1 (Kilić et al., 2010). 
As well NFAT3 translocation after 24h treatment with angiotensin II was assessed 
via western blot of nuclear fractions of cardiomyocytes. Angiotensin II significantly 
increased NFAT3 translocation to the nucleus which was attenuated by calcineurin 
inhibitor FK506. This finding is also in concordance with a  study that demonstrated 
NFAT3 translocation to the nucleus at 24 hours after treatment with either angiotensin II, 
endothelin-1 or phenylephrine—agonists that activate the NHE-1/calcineurin signalling 
pathway (Kilić et al., 2010). 
These findings suggest that the NHE-1/calcineurin signalling pathway is being 
activated by angiotensin II via an AT-1 dependent mechanism. Administration of the AT-
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1 antagonist, NHE-1 inhibitor or calcineurin inhibitor shuts down angiotensin II’s ability 
to signal through this pathway, a pathway which is critical for regulation of FTO in the 
cardiomyocyte. 
4.6 Leptin receptor blockade attenuates angiotensin II-
induced hypertrophy 
Cardiomyocytes treated for 24 h with angiotensin II induced hypertrophy as 
evidenced by an increase in cell surface area and α-skeletal actin gene expression. These 
increases are attenuated by the super-ovine leptin receptor antagonist (LRA). These 
findings are not unique, as our lab has demonstrated in the past that angiotensin II’s ability 
to induce hypertrophy can be abolished by antagonizing the leptin signalling system 
(Rajapurohitam et al., 2006). As described in the aforementioned study, angiotensin II is 
able to upregulate the synthesis and secretion of leptin from the cardiomyocyte, which in 
turn, has an autocrine effect on the cardiomyocyte. When the autocrine effect of leptin is 
blocked, angiotensin II-induced hypertrophy is also abolished. 
4.7 Leptin receptor blockade attenuates angiotensin II-
induced FTO upregulation 
Angiotensin II’s ability to increase FTO expression cannot solely be explained by 
the NHE-1/calcineurin signalling pathway. This is because this is a Gq protein mediated 
pathway—a pathway through which phenylephrine works through as well. However 
phenylephrine was unable to increase FTO expression. Thus we decided to look at alternate 
mechanisms that could explain the disparity between angiotensin II’s and phenylephrine’s 
effect on FTO expression. Based on the conclusions from Rajapurohitam et al. about 
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angiotensin II-induced leptin autocrine signalling, and the recent study published by our 
lab on leptin’s effect on FTO expression (Gan et al., 2013), we found leptin signalling a 
suitable candidate to explain why angiotensin II possessed the ability to upregulate FTO 
and why phenylephrine did not. Thus we formulated the hypothesis that angiotensin II 
induced FTO upregulation was, in part, mediated by leptin. We decided to look at some of 
the same markers studied in the leptin-FTO study (Gan et al., 2013), as we believed that 
the same pathway was being indirectly activated by angiotensin II. 
In this current study angiotensin II-induced FTO upregulation was attenuated by 
LRA. This unique finding was supplemented with some gene expression data of other 
markers. The proteolytic enzyme cathepsin L and transcription factor CUX1 both increased 
in gene expression after 24 h angiotensin II treatment. These increases were also attenuated 
by LRA. Increases in these markers in response to leptin were also observed in the study 
published by Gan.  This strengthens the notion that angiotensin II works through the leptin 
signalling pathway displayed in figure 2 in order to achieve FTO upregulation 
4.8 Angiotensin II activates JAK2 and STAT3; the molecular 
mediators of leptin-induced FTO upregulation 
In this current study angiotensin II activated JAK2 and STAT3 in a time dependent 
fashion. 15 minute angiotensin II treatment activated JAK2 in the cardiomyocyte. STAT3 
appeared to be activated at the 60 minute angiotensin II treatment time point. This lends 
support to the notion that angiotensin II is activating the leptin signalling system as JAK2 
and STAT3 are important molecular mediators of leptin-induced FTO upregulation. In the 
study published by Gan in 2013, they demonstrated suppression of FTO and phospho-
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STAT3 in the hearts of animals that had been treated with a leptin receptor antibody (Gan 
et al., 2013). In addition, they demonstrated an increase in phospho-STAT3 and an increase 
in JAK2 gene and protein expression after 24 h leptin treatment (Gan et al., 2013).  Another 
study also displays a role for STAT3 in mediating leptin’s effect on FTO expression in 
mice hypothalamic nuclei (Wang et al., 2011). Leptin downregulates FTO in the arcuate 
nuclei of these mice through a STAT3 mediated mechanism (Wang et al., 2011). 
Gan et al. demonstrate that JAK2 and STAT3 play a critical role in leptin induced 
FTO regulation. Moreover, it is plausible that angiotensin II is indirectly activating these 
molecular mediators via an increase leptin signalling. 
4.9 Angiotensin II-induced hypertrophy and FTO 
upregulation is attenuated by JAK2 inhibitor AG490 
Hypertrophy of cardiomyocytes after 24 h treatment with angiotensin II was 
abolished by JAK2 inhibitor AG490. Cell surface area and α-skeletal actin gene expression 
were brought back down to basal levels with AG490. Thus it appears that JAK2 signalling 
plays a critical role in angiotensin II induced hypertrophy, and lends support to the 
hypothesis that interruption of the leptin-JAK2-STAT3 signalling pathway can nullify 
angiotensin II’s ability to induce the hypertrophic program. 
AG490 also attenuated angiotensin II-induced FTO upregulation in the 
cardiomyocyte. This was evidenced by a return to basal levels of FTO gene expression and 
FTO protein expression. This finding directly links angiotensin II’s ability to upregulate 
FTO to the molecular mediator JAK2. As well, AG490 attenuated angiotensin II-induced 
increases in gene expression of cathepsin L—the protease responsible for cleaving p200 
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CUX1 into the active transcription factor for FTO (p110 CUX1)—and CUX1—the gene 
that gives rise to CUX1 protein. A similar finding was displayed in the study published by 
Gan in 2013 where AG490 was able to attenuate leptin-induced increases in FTO and 
cathepsin L expression. 
This is further support that angiotensin II is upregulating FTO, in part, by increasing 
leptin autocrine signalling resulting in the same intracellular signalling pathway proposed 
in the Gan’s study (figure 2). 
4.10 Leptin-induced cardiomyocyte hypertrophy and FTO 
upregulation is attenuated by calcineurin inhibitor 
FK506 but not NHE-1 inhibitor EMD87580 
In this study we have been able to elucidate the mechanisms behind angiotensin II-
induced FTO regulation. We have been able to determine that the NHE-1/calcineurin 
signalling system and angiotensin II- induced leptin autocrine signalling system play 
critical roles in regulating the hypertrophic protein FTO. Both of these pathways have been 
studied in isolation and both have proven necessary for the regulation of FTO. Thus it is 
plausible that because angiotensin II activates both these pathways, and both of these 
pathways have a commonality in upregulating FTO, these pathways may share some 
crosstalk, overlap or work in a synergistic fashion to manifest FTO upregulation. To study 
this hypothesis we used the NHE-1 inhibitor EMD87580 and the calcineurin inhibitor 
FK506 to study if NHE-1 and calcineurin were involved in leptin’s regulation of FTO and 
leptin’s induction of the hypertrophic process. As evidenced by cell surface area, 
EMD87580 did not attenuate the leptin-induced increase in cell size. In contrast, FK506 
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was able to attenuate the leptin-induced increase in cell surface area. This finding was 
similar to a finding in another study where leptin induced hypertrophy was abrogated by 
calcineurin inhibitor FK506 as evidenced by attenuation in the increases of cell surface 
area, α-skeletal actin gene expression and leucine incorporation (Rajapurohitam et al., 
2012). Thus it appears angiotensin II and leptin share a molecular mediator when it comes 
to induction of the hypertrophic process—calcineurin. 
EMD87580 was also unable to attenuate the leptin-induced upregulation of FTO further 
suggesting that NHE-1 is not involved in leptin’s hypertrophic signalling pathway and 
establishing that NHE-1 is not involved in leptin induced FTO regulation. However, in 
agreement with the hypertrophic assessment, FK506 did attenuate leptin’s ability to 
upregulate FTO. Thus calcineurin plays a critical role in leptin-induced FTO upregulation. 
Similar to hypertrophy it appears that calcineurin is both critical for angiotensin II and 
leptin’s ability to upregulate FTO. 
It appears that calcineurin and JAK2/STAT3 mechanisms may be working in a 
concerted or synergistic fashion to produce FTO upregulation in angiotensin II treated 
cardiomyocytes. Other studies have explored the interaction of calcineurin and 
JAK2/STAT3 albeit in other cell types. One study demonstrates that calcineurin can 
dephosphorylate STAT3 thus terminating SIF-SIE (sis inducing factor-sis inducing 
element) interactions in vascular smooth muscle cells treated with angiotensin II (Liang et 
al., 1999). Although this is a system studied in vascular smooth muscle cells, the interaction 
between calcineurin and JAK2/STAT3 explained in this particular study would be in 
opposition to the plausible scenario suggested in this study between the two pathways. We 
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would expect calcineurin to positively regulate the JAK2/STAT3 pathway or the 
JAK2/STAT3 pathway to facilitate calcineurin activation. However another study 
demonstrates that FK506 suppresses activation of the JAK/STAT pathway by interleukin-
6 in fibroblast-like synoviocytes, intimating that calcineurin activation facilitates 
JAK2/STAT3 activation in this cell type (Choe et al., 2013). This study supports the 
hypothetical notion that in cardiomyocytes, calcineurin and JAK2/STAT3 may work in 
concert or synergistically to upregulate FTO and induce hypertrophy. 
4.11 Significance and clinical perspective of the study 
Heart failure is an imminent burden on our health care system as we are facing an 
aging population. As well, advancements in medicine for treatments of heart attacks have 
resulted in an increase in survival. Unfortunately this increase in survival of cardiac 
patients leads to an increased probability of developing heart failure as a result of 
compromised heart function. One of the main features of heart failure is pathological 
cardiac hypertrophy. This hypertrophic response becomes deleterious to heart function 
which leads to heart failure. Elucidating the major hypertrophic mechanisms that take place 
during heart failure, and identifying specific molecular targets for therapeutic intervention 
is critical for not only the treatment but also the prevention of heart failure. In this study 
we have been able to characterize angiotensin II’s ability to upregulate FTO, a protein 
suggested to be hypertrophic in the heart. We have elucidated specific hypertrophic 
signalling pathways linked to the upregulation of FTO in angiotensin II treated 
cardiomyocytes. FTO seems to be inextricably tied to signalling pathways responsible for 
pathological cardiac hypertrophy. FTO provides yet another target for pharmacological 
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intervention in which we can slow down or reverse the development of pathological 
hypertrophy resulting in better prognoses for heart failure. 
4.12 Conclusion 
Our major conclusion in this study is that angiotensin II upregulates the fat mass and 
obesity associated protein (FTO) in the cardiomyocyte. Angiotensin II joins only leptin as 
the only other hypertrophic agonist to increase FTO expression in the cardiomyocyte. 
Angiotensin II’s ability to regulate FTO expression is AT-1 receptor mediated. The 
intracellular signalling pathways involved in angiotensin II’s upregulation of FTO are the 
NHE-1/calcineurin signalling pathway and the leptin-dependent JAK2/STAT3 signalling 
pathway. These pathways plausibly act in concert or exhibit some type of crosstalk (Figure 
18), as antagonizing either pathway in isolation abolishes angiotensin II induced FTO 
upregulation, suggesting a common critical juncture through which both pathways cross to 
achieve FTO upregulation. 
There are usually a multitude of pathways activated in response to one signal. Moreover 
these pathways usually result in the same molecular manifestation. The redundancy of 
cellular mechanisms for a certain cellular process highlights the importance of that cellular 
process. It is important to understand all these intracellular mechanisms in isolation, and 
more important to identify areas of cross talk once we have studied these mechanisms in 
isolation. True understanding of the pathological hypertrophic process is dependent upon 
understanding how the mechanisms relate to each other. 
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Figure 18. Proposed signalling and crosstalk mechanisms for angiotensin II-induced 
FTO upregulation. Angiotensin II activates a Gq-mediated NHE-1/calcineurin 
signalling pathway and leptin-mediated JAK2/STAT3 signalling pathway, with both 
pathways having a plausible common and critical point of interaction necessary for FTO 
upregulation.   
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AUP Number: 2013-031   
PI Name: Karmazyn, Morris   
AUP Title: Heart failure    
Official Notification of AUS Approval: A MODIFICATION to Animal Use Protocol 
2013031  
has been approved.    
The holder of this Animal Use Protocol is responsible to ensure that all associated safety  
components (biosafety, radiation safety, general laboratory safety) comply with 
institutional safety  
standards and have received all necessary approvals. Please consult directly with your 
institutional  
safety officers.    
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